Your session is about to expire
← Back to Search
Nonsteroidal Anti-inflammatory Drug (NSAID)
Topical, intra-oral ketoprofen gel for Migraine
Phase 3
Waitlist Available
Led By Caren Behar, MD
Research Sponsored by Behar, Caren, M.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
Pivotal Trial
Summary
This trial is testing a mouth-applied pain reliever called ketoprofen to see if it helps people with sudden migraine attacks. The goal is to find out if it works well and is safe to use. Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that has been tested in various formulations for the treatment of acute migraine attacks.
Eligible Conditions
- Migraine
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: Topical, intra-oral ketoprofen gelActive Control1 Intervention
Group II: Placebo gelPlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
Behar, Caren, M.D.Lead Sponsor
1 Previous Clinical Trials
67 Total Patients Enrolled
1 Trials studying Migraine
67 Patients Enrolled for Migraine
Caren Behar, MDPrincipal InvestigatorNew York Medical College
1 Previous Clinical Trials
67 Total Patients Enrolled
1 Trials studying Migraine
67 Patients Enrolled for Migraine
Share this study with friends
Copy Link
Messenger